Chardan Capital Maintains Buy on Krystal Biotech, Raises Price Target to $208
Portfolio Pulse from Benzinga Newsdesk
Chardan Capital has maintained its Buy rating on Krystal Biotech (NASDAQ:KRYS) and raised the price target from $153 to $208.
August 05, 2024 | 10:31 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Chardan Capital has maintained its Buy rating on Krystal Biotech and raised the price target from $153 to $208, indicating strong confidence in the company's future performance.
The raised price target from $153 to $208 by Chardan Capital suggests a positive outlook for Krystal Biotech, likely leading to increased investor confidence and a potential rise in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100